{"id":11292,"date":"2022-08-26T12:00:00","date_gmt":"2022-08-26T12:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3855849_CN55849_0"},"modified":"2022-08-26T12:00:00","modified_gmt":"2022-08-26T12:00:00","slug":"first-approval-of-cadonilimab-pd-1-ctla-4-bispecific-published-in-drugs-a-peer-reviewed-medical-journal","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=11292","title":{"rendered":"First approval of Cadonilimab (PD-1\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal"},"content":{"rendered":"
\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

HONG KONG<\/span><\/span>, Aug. 26, 2022<\/span><\/span> \/PRNewswire\/ — Akeso, Inc. <\/b>(9926.HK) (“Akeso”), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring on Cadonilimab<\/span>, a first-in-class PD-1\/CTLA-4 bi-specific antibody developed by the company, was published in Drugs<\/i>, a peer-reviewed medical journal specializing in pharmaceutics.<\/p>\n

Article link: https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01761-9<\/a><\/span><\/p>\n

The article provides an in-depth and comprehensive summary of the prospective drug design rationale of Cadonilimab, clinical trials progress in different tumors, and milestones in the development of Cadonilimab leading to its first approval.<\/p>\n

Cadonilimab received its first approval on June 2022<\/span> in China<\/span> for use in patients withrelapsed or metastatic cervical cancer (r\/m CC) who have progressed on or after platinum-based chemotherapy. Cadonilimab is the globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing. It is worth mentioning that the approval of Cadonilimab not only marks China’s<\/span> innovative biotech companies starting to reap the fruits after years of R&D investments but also demonstrates that Chinese biotech companies represented by Akeso are closing the gap with global pharmaceutical companies rapidly in innovative drug development.<\/p>\n

There are many ongoing trials of Cadonilimab as monotherapy or combination therapy for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric\/gastroesophageal junction cancer, oesophageal squamous cell cancer, liver cancer, and nasopharyngeal cancer.<\/p>\n

In addition to Cadonilimab, Akeso also promotes many drug candidates efficiently. Ivonescimab (PD-1\/VEGF bi-specific antibody, AK112), the second globally first-in-class bi-specific antibody, is in phase III trials, and the third bi-specific antibody(PD-1\/LAG-3) is about to enter the clinical stage. Akeso hopes to bring more innovative high-quality biologics to the market for the benefit of patients worldwide.<\/p>\n

For 50 years, Drugs<\/i> has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making. In 2022, Drugs<\/i> has an impact factor of 11.431.<\/p>\n

\"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/first-approval-of-cadonilimab-pd-1ctla-4-bispecific-published-in-drugs-a-peer-reviewed-medical-journal-301613079.html<\/a><\/p>\n<\/p><\/div>\n

Source: Akeso, Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"

HONG KONG, Aug. 26, 2022 \/PRNewswire\/ — Akeso, Inc. (9926.HK) (“Akeso”), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring on Cadonilimab, a first-in-class PD-1\/CTLA-4 bi-specific antibody developed by the company, was published in Drugs, a peer-reviewed medical journal specializing in pharmaceutics. […]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-11292","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"\nFirst approval of Cadonilimab (PD-1\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=11292\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First approval of Cadonilimab (PD-1\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal - My Blog\" \/>\n<meta property=\"og:description\" content=\"HONG KONG, Aug. 26, 2022 \/PRNewswire\/ — Akeso, Inc. (9926.HK) (“Akeso”), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring on Cadonilimab, a first-in-class PD-1\/CTLA-4 bi-specific antibody developed by the company, was published in Drugs, a peer-reviewed medical journal specializing in pharmaceutics. […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=11292\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-26T12:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1797099\/logo_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"First approval of Cadonilimab (PD-1\\\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal\",\"datePublished\":\"2022-08-26T12:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292\"},\"wordCount\":362,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1797099\\\/logo_Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292\",\"name\":\"First approval of Cadonilimab (PD-1\\\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1797099\\\/logo_Logo.jpg?p=medium600\",\"datePublished\":\"2022-08-26T12:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1797099\\\/logo_Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1797099\\\/logo_Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=11292#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First approval of Cadonilimab (PD-1\\\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First approval of Cadonilimab (PD-1\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=11292","og_locale":"en_US","og_type":"article","og_title":"First approval of Cadonilimab (PD-1\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal - My Blog","og_description":"HONG KONG, Aug. 26, 2022 \/PRNewswire\/ — Akeso, Inc. (9926.HK) (“Akeso”), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring on Cadonilimab, a first-in-class PD-1\/CTLA-4 bi-specific antibody developed by the company, was published in Drugs, a peer-reviewed medical journal specializing in pharmaceutics. […]","og_url":"https:\/\/transmediavictoria.net.au\/?p=11292","og_site_name":"My Blog","article_published_time":"2022-08-26T12:00:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1797099\/logo_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=11292#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11292"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"First approval of Cadonilimab (PD-1\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal","datePublished":"2022-08-26T12:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11292"},"wordCount":362,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11292#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1797099\/logo_Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=11292","url":"https:\/\/transmediavictoria.net.au\/?p=11292","name":"First approval of Cadonilimab (PD-1\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11292#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11292#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1797099\/logo_Logo.jpg?p=medium600","datePublished":"2022-08-26T12:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=11292#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=11292"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=11292#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/1797099\/logo_Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/1797099\/logo_Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=11292#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"First approval of Cadonilimab (PD-1\/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/11292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11292"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/11292\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}